Company Accelerate Diagnostics, Inc.

Equities

AXDX

US00430H2013

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.99 USD -1.98% Intraday chart for Accelerate Diagnostics, Inc. +1.00% -74.74%

Business Summary

Accelerate Diagnostics, Inc. is an in-vitro diagnostics company. The Company is engaged in providing solutions that improve patient outcomes through the diagnosis of serious infections. Its in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit. The Accelerate PhenoTest BC Kit, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk.

Number of employees: 179

Sales per Business

USD in Million2021Weight2022Weight Delta
Accelerate Pheno
98.8 %
12 98.7 % 13 98.8 % +8.34%
Other
1.2 %
0 1.3 % 0 1.2 % 0.00%

Sales per region

USD in Million2021Weight2022Weight Delta
United States
85.6 %
10 85.9 % 11 85.6 % +7.90%
Foreign
14.4 %
2 14.1 % 2 14.4 % +10.23%

Managers

Managers TitleAgeSince
Chief Executive Officer 58 19-07-31
Director of Finance/CFO 38 17-08-31
Chief Operating Officer - 22-12-31
Chief Tech/Sci/R&D Officer - 21-04-30
Investor Relations Contact - -
Sales & Marketing - 18-09-30
Corporate Officer/Principal - 16-02-29

Members of the board

Members of the board TitleAgeSince
Director/Board Member 76 12-06-25
Director/Board Member 83 12-06-25
Director/Board Member 71 19-12-01
Chairman 62 21-05-19
Director/Board Member 51 12-07-06
Director/Board Member 55 23-05-18
Director/Board Member 69 22-02-01
Chief Executive Officer 58 19-07-31
Director/Board Member - 23-05-18
Director/Board Member - 23-05-17

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 20,085,267 13,359,653 ( 66.51 %) 0 66.51 %

Shareholders

NameEquities%Valuation
6,962,785 34.35 % 7 M $
Griffin Asset Management, Inc.
6.017 %
1,219,724 6.017 % 1 M $
Griffin Asset Management, Inc.
6.017 %
1,219,724 6.017 % 1 M $
671,211 3.311 % 661 143 $
Vanguard Global Advisers LLC
1.513 %
306,637 1.513 % 302 037 $
Birchview Capital LP
1.111 %
225,239 1.111 % 221 860 $
204,556 1.009 % 201 488 $
Birchview Capital LP
0.5953 %
120,682 0.5953 % 118 872 $
Cannell & Co.
0.5658 %
114,690 0.5658 % 112 970 $
Oracle Investment Management, Inc.
0.5504 %
111,575 0.5504 % 109 901 $

Company contact information

Accelerate Diagnostics, Inc.

3950 South Country Club Road Suite 470

85714, Tucson

+520 365 3100

http://acceleratediagnostics.com
address Accelerate Diagnostics, Inc.(AXDX)